> Business Development

Medivation, Inc. (NASDAQ: MDVN) has licensed exclusive worldwide rights to CureTech’s late-stage clinical molecule pidilizumab (CT-011). Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications.